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Disulfide bonds are rare in bacterial natural products,
and the mechanism of disulfide bond formation in
those products is unknown. Here we characterize
a gene and its product critical for a disulfide bond
formation in FK228 anticancer depsipeptide in Chro-
mobacterium violaceum. Deletion of depH drastically
reduced FK228 production, whereas complementa-
tion of the depH-deletion mutant with a copy of
depHonamediumcopy-numberplasmidnotonly fully
restored the FK228 production but also significantly
increased the FK228 yield. Purified 6xHis-tagged
DepH fusion protein in native form is a homodimer of
71.0 kDa, with each monomer containing one mole-
cule of FAD. DepH efficiently converts an immediate
FK228 precursor to FK228 in the presence of NADP+.
Weconclude thatDepH is anFAD-dependentpyridine
nucleotide-disulfide oxidoreductase, specifically and
efficiently catalyzing a disulfide bond formation in
FK228.
INTRODUCTION
Disulfide bonds that link two nonadjacent cysteine residues
often exist in ribosomally synthesized proteins and peptides as
well as their derived products, such as lantibiotics, toxins,
venoms, and hormones, to maintain proper folding configura-
tion, to mediate redox cycling of enzyme activity, or to regulate
a protein’s activation and deactivation (Giles et al., 2003; Kado-
kura et al., 2003). Proteins that are capable of catalyzing protein/
peptide disulfide bond formation are members of a large collec-
tion of thiol-disulfide oxidoreductases found in all living cells.
Many of these enzymes belong to the thioredoxin superfamily,
which is defined by an active site containing a CXXC redox motif
(cysteines separated by two amino acids) and by a thioredoxin
fold seen in three-dimensional structure of the prototypical thio-
redoxin 1 of E. coli (Lennon et al., 1999; Waksman et al., 1994).
The most studied catalysts for disulfide bond formation are
the Dsb-family of proteins (DsbA, DsbB, DsbC, and DsbD) of
E. coli (Bardwell et al., 1991; Martin et al., 1993; Nakamoto and
Bardwell, 2004). Other enzymes that are not members of theChemistry & Biology 16thioredoxin superfamily but use redox active cysteine residues
in transferring electrons in oxidative and reductive pathways
have entirely different three-dimensional structures from thio-
redoxin. They might use small molecule electron donors and
acceptors, such as FAD, NAD+/NADH, NADP+/NADPH,
quinone, or lipoic acid (Bryk et al., 2002).
Disulfide bonds are also found in small molecules (natural
products) made nonribosomally by a serial of biochemical reac-
tions catalyzed by enzymes other than the ribosomal machinery.
Most of those natural products are produced by garlic plants or
fungi (Jacob, 2006) and a feware producedby bacteria (Figure 1),
but the enzymology of disulfide bond formation in those products
is largely unknown. Based on a study of heterologous production
of echinomycin in E. coli, Watanabe et al. proposed the Ecm17
protein (encodedby ecm17gene in the echinomycin biosynthetic
gene cluster) as an oxidoreductase that catalyzes the formation
of a disulfide bond in a triostin Aprecursor to afford triostin A (Wa-
tanabe et al., 2006), but there was no biochemical evidence to
support this plausible notion. Disulfide bond in triostin A is not
critical for bioactivities because it can be further modified by
a SAM-dependent methyltransferase to form a thioacetal bond
in the final product echinomycin. Triostin A is a member of the
quinoxaline family of antibiotics that also include BE-22179,
SW-163C, and thiocoraline (Dawson et al., 2007) (Figure 1). There
is no molecular genetic study of the biosynthesis of BE-22179 or
SW-163C. Surprisingly the thiocoraline biosynthetic gene cluster
does not contain a gene encoding an Ecm17-like enzyme or, in
a broad sense, a thioredoxin-like oxidoreductase (Lombo et al.,
2006). It is unclear whether the disulfide bond in thiocoraline is
formed by an unidentified enzyme encoded by a gene indepen-
dent of the gene cluster or simply by chemical oxidation. Finally,
the biogenesis of a disulfide bond in FR901,375 (Masakuni et al.,
1991), spiruchostatins (Masuoka et al., 2001), somocystinamide
A (Nogle and Gerwick, 2002), or a dithiolane bond in leinamycin
(Tang et al., 2004), remains to be elucidated.
FK228 (depsipeptide; Figure 1) is a rare disulfide-containing
natural product produced by Gram-negative Chromobacterium
violaceum No. 968 as a prodrug (Shigematsu et al., 1994;
Ueda et al., 1994). Prodrug FK228 can diffuse across the cell
membrane and be readily activated by intracellular reduction of
the disulfide bond inside the cytoplasmic environment of
mammalian cells. Upon activation, the freed thiol group on the
longer aliphatic tail of reduced FK228 fits inside the catalytic
pocket of preferred class I histone deacetylases (HDACs),, 585–593, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 585
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jima et al., 1998). Selective but modest inhibition of HDACs leads
to a cascade of chromatin remodeling, tumor suppressor gene
reactivation, apoptosis, and regression of cancer (Bolden
et al., 2006). FK228 has become one of the most promising
anticancer agents specifically intervening cancer epigenetics
(Yoo and Jones, 2006).
Aimed at diversification and optimization of FK228 through
metabolic engineering, combinatorial biosynthesis, and chemo-
enzymatic synthesis, we previously cloned and partially charac-
terized the FK228 biosynthetic gene cluster (designated as dep
for depsipeptide). Based on the deduced protein functions
of dep genes, we proposed an unusual hybrid nonribosomal
peptide synthetase (NRPS)-polyketide synthase-NRPS pathway
for FK228 biosynthesis in C. violaceum no. 968 (Cheng et al.,
2007). This pathway would lead to the production of an imme-
diate FK228 precursor (reduced FK228) with two free thiol
groups from cysteine residues (Figure 1). Furthermore, we
proposed DepH as a putative FAD-dependent pyridine nucleo-
tide-disulfide oxidoreductase, encoded by depH, to catalyze
a disulfide bond formation between two thiol groups as the final
step in FK228 biosynthesis.
Here we report genetic and biochemical evidence in support
of DepH as an FAD-dependent pyridine nucleotide-disulfide
oxidoreductase, specifically and efficiently catalyzing a disulfide
bond formation in FK228. To our best knowledge, this work
represents the first biochemical characterization of an enzyme
involved in the formation of a disulfide bond in a nonribosomally
produced bacterial natural product.
RESULTS
Protein Sequence Analysis of DepH
Gene depH in the FK228 biosynthetic gene cluster has an open
reading frame (ORF) of 960 bp and was predicted to encode a
319-amino-acid FAD-dependent pyridine nucleotide-disulfide
oxidoreductase, DepH (GenBank accession number ABP57752),
that converts two thiol groups from cysteines into a disulfide
Figure 1. FK228 Biosynthetic Gene Cluster
and Structures of Disulfide- or Dithiolane-
Containing Natural Products Produced
Nonribosomally by Bacteria
Gene depH is depicted as one of the three post-
nonribosomal peptide synthetase (NRPS; dark
red)/polyketide synthase (PKS; orange) tailoring
genes (yellow). All natural products listed here
have and are expected to have anticancer activi-
ties. Conceptual conversions from precursor (the
immediate precursor of FK228 or triostin A) to
product (FK228 or triostin A) by enzyme (DepH or
Ecm17, respectively) are indicated. Disulfide and
dithiolane bonds are highlighted by a yellow oval
background shading.
bond as the final step of FK228 biosyn-
thesis (Cheng et al., 2007). Primary
sequence of DepH shares a 72% iden-
tity/85% similarity to a hypothetical
protein (GenBank accession number
ABC38333; named TdpH in our ongoing work) of Burkholderia
thailandensis E264 (Kim et al., 2005), and shares modest
percentages of identity/similarity to a few hypothetical proteins
of Pseudomonas, Sinorhizobium, or Cellvibrio species. Neither
the DepH nor the TdpH sequence has more than 34% identity/
46% similarity to the deduced Ecm17 sequence of the ecm17
gene in the triostin A/echinomycin biosynthetic gene cluster in
S. lasaliensis (Watanabe et al., 2006). A phylogenetic analysis
of the sequences of DepH and its closest homologs, and other
well-studied proteins involved in disulfide bond formation in pro-
teogenic products, suggests that an active site containing
a CXXC redox motif is conserved in all related proteins; but
DepH, TdpH, Echm17 and a few hypothetical proteins constitute
a distinctive clade (group 1) of proteins with a CPY/FC motif,
which is clearly different from that (CAT/VC) of the thioredoxin
reductase (TrxB/TrxR) family of enzymes (group 2) or that
(CXXC; X represents any less conserved residue) of the Dsb-
family of enzymes (group 3) (Figure 2A). Site-directed mutagen-
esis experiments have confirmed the catalytic essentiality of
both cysteine residues in the CPYC redox motif of DepH (see
Enzyme Activity and Kinetics). Furthermore, DepH can be
dissected into an FAD-binding domain, an NADP+/NADPH-
binding domain and two terminal regions, according to its orga-
nizational similarity to the TrxR of Mycobacterium tuberculosis
(Akif et al., 2005) (Figure 2B).
Genetic Confirmation of the Involvement of depH
in FK228 Biosynthesis
We adopted and further improved an efficient, broad host-range
genetic system for gene deletion, marker removal, and gene
complementation in C. violaceum No. 968, and potentially in
a wide range of other Gram-negative bacteria (Cheng et al.,
2007; see Supplemental Data available online). Subsequently
we created two lines of C. violaceum depH mutant (Table S1;
Figures S1 and S2). In mutant CvDdepH::FRT, a 555 bp internal
part of depH is replaced by an FRT cassette from pPS858
(Hoang et al., 1998). Due to a concern about a potential polar
effect on the functioning of downstream genes (see the dep
586 Chemistry & Biology 16, 585–593, June 26, 2009 ª2009 Elsevier Ltd All rights reserved
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Disulfide Bond Formation in FK228gene cluster organization in Figure 1), we excised the FRT
cassette from CvDdepH::FRT by a site-specific Flp endonu-
clease encoded by vector pBMTL3-FLP2 and created
a marker-free mutant CvDdepH with only a 85 bp scar left at
the site of gene deletion. Furthermore, we complemented this
CvDdepH mutant with a copy of depH on a medium copy-
number expression vector (pBMTL3-depH), resulting in a com-
plementant strain CvDdepH/pBMTL3-depH.
Examination of FK228 production in the wild-type strain
(CvWT), CvDdepH mutant strain, CvDdepH/pBMTL3-depH
complementant strain, and aCvWT/pBMTL3-depHcontrol strain
of C. violaceum by liquid-chromatography mass spectrometry
(LC-MS) analysis revealed very interesting results (Figure 3). First,
consistent with a previous study (Cheng et al., 2007), the CvWT
strain produced a signature profile of three FK228 ion adducts,
[M + H]+ = 540.3 m/z, [M + Na]+ = 563.3 m/z, and [M + K]+ =
579.3 m/z. Second, the CvDdepH mutant strain produced
much less FK228 (20%of thewild-type level).When the sample
extract of this strainwas concentrated 5-fold and analyzed again,
a shoulder ion signal peak right next to each main signal peak
became noticeable. When we zoomed in, we found that those
shoulder peaks had a +2 m/z value corresponding to each of
the main signal peaks. Those signals, [M + 2 + H]+ = 542.4 m/z,
[M + 2 + Na]+ = 565.4 m/z, and [M + 2 + K]+ = 581.3 m/z, were
apparently from an immediate FK228 precursor—the unoxidized
(reduced) precursor with two free thiols (Figure 1). Furthermore,
Figure 2. Sequence Analyses of DepH
(A) Phylogenetic analysis of DepH, its closest homologs, and representative
bacterial proteins involved in protein/peptide disulfide bond formation. Amino
acid sequences were obtained from the GenBank database, alignment was
performed with ClustalW program (Chenna et al., 2003) and phylogenetic
tree is presented as a rooted dendrogram. Each protein sequence is labeled
by a strain name followed by a protein namewhere available, or by ‘‘Hp’’ (hypo-
thetical protein). Database accession numbers are listed in the separate
column. The redox motif (CXXC) of each protein was extracted from aligned
sequences. Proteins are classified into three groups according to their phylo-
genetic relationships and their redox motif residues.
(B) Scheme of domain organization and the position of the redox motif of
DepH.Chemistry & Biology 16the CvDdepH/pBMTL3-depH complementant strain not only re-
gained FK228 production, but also produced about 30% more
FK228 than the CvWT strain, indicating that the DepH-catalyzed
disulfide bond formation is a rate-limiting step in FK228 biosyn-
thesis inside the reducing environment of bacterial cells. Finally,
the CvWT/pBMTL3-depH control strain indeed produced signif-
icantly (34%)more FK228 than theCvWTstrain, confirming that
DepH-catalyzed disulfide bond formation is the rate-limiting step
in FK228 biosynthesis.
Overexpression, Purification and Initial
Characterization of DepH
DepH was overexpressed as an N-terminal 6xHis-tagged fusion
protein and was purified using Ni-NTA agarose chromatography






Figure 3. Detection and Quantification of FK228 Production by
LC-MS Analysis
The relative abundance of FK228 production is estimated by the sum of ion
signals from three signature peaks of each strain/sample.
(A) Sample from the wild-type strain (CvWT).
(B) 1X and 5X concentrated samples of the depH-deletion mutant strain
CvDdepH.
(C) Sample from the CvDdepH/BMTL3-depH complementant strain.
(D) Sample from the CvWT/BMTL3-depH control strain., 585–593, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 587
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Disulfide Bond Formation in FK228conditions specified in Experimental Procedures. On SDS-PAGE
gel, denatured 6xHis-tagged DepH appeared to have a molec-
ular mass of approximately 36.5 kDa (including a 2.1 kDa
6xHis tag) (Figure 4A). The minor protein band migrating slightly
in front of the major band might result from weak protein
cleavage at a specific point, even though a protease inhibitor
cocktail was added to buffers during purification steps. Without
the presence of a reducing agent in our purification scheme,
DepH is expected to exist in an oxidized form with an intact
disulfide bond formed at the CPYC redox motif/catalytic site
(Figure 2B). By size exclusion chromatography, native 6xHis-
tagged DepH was determined to have an apparent molecular
mass of 71.0 kDa (Figure 4B). These results suggest that DepH
exists as a homodimer under native conditions.
Identification of FAD as a Cofactor of DepH
Several lines of evidence suggested the presence of FAD
cofactor in DepH. First, purified 6xHis-tagged DepH has
a distinctive yellow color, indicating the presence of a flavin pros-
thetic group. Second, the major absorption wavelengths of
DepH were at 377 nm and 455 nm, which are comparable with
those of an FAD standard (Figure 4C). Third, to confirm FAD as
the cofactor, DepH was denatured and the denatured protein
was cleared by centrifugation. The supernatant retained the
distinctive yellow color, suggesting that the suspected cofactor
is not covalently bound to the protein. Subsequently, the super-
natant was subjected to high-performance liquid chromatog-
raphy (HPLC) analysis, alongwith FAD as a control. The superna-
tant generated a HPLC profile that is essentially identical to that
of FAD standard in terms of retention time and peak shape
Figure 4. Purification and Characterization of DepH
(A) Ni-NTA affinity-purified DepH was visualized on a SDS-PAGE gel.
(B) Themolecular mass of DepHwas determined by size exclusion chromatog-
raphy. Protein standards were used to generate a standard curve. The inset
shows an elution profile of DepH bracketed by two protein standards.
(C) UV/Vis absorbance spectra of DepH and an FAD standard. The concentra-
tions of FAD standard and DepH were 25 mM and 36 mM, respectively, both in
20 mM Tris-HCl (pH 7.0) and 100 mM NaCl buffer.588 Chemistry & Biology 16, 585–593, June 26, 2009 ª2009 Elsevie(Figure S3). Finally, the suspected cofactor peak was collected
fromHPLC and analyzed by LC-MS. The sample yielded a signal
of 785.3 m/z, which is in agreement with the ion signal of FAD
standard (Figure S3 inserts).
The DepH-FAD stoichiometry was approximately 1.1 to 1,
suggesting that each monomeric DepH contains one molecule
of FAD cofactor. This is consistent with a generalized observa-
tion regarding the flavoprotein disulfide reductase-family of
enzymes (Argyrou and Blanchard, 2004).
Enzyme Activity and Kinetics
To assay the enzyme activity of DepH in catalyzing the conver-
sion of an immediate FK228 precursor (reduced FK228) to
FK228 (Figure 1), reduced FK228 was freshly prepared by
reducing FK228 with an excess amount of DTT in acetonitrile/
water (20% v/v), purified with preparative HPLC, dried in vacuo,
and kept airtight at 20C. Prior to assays, an appropriate
amount of reduced FK228 in amorphous state was resuspended
in acetonitrile to approximately 0.54 mg/ml (1.0 mM).
For qualitative assays performed in duplicate, a fixed amount
of substrate (reduced FK228) was mixed with a fixed amount of
enzyme (DepH) in an appropriate buffer for 5min at room temper-
ature in a nitrogen environment. The reaction mixture was then
quenched and subjected to LC-MS analysis. Due to unavoidable
spontaneous chemical oxidation during prior purification,
storage, and resuspension steps, a control assay that was
without enzyme and kept at 80C had approximately 40%
substrate oxidized (Figure 5A); a second control assay that was
Figure 5. In Vitro Assays of DepH in Converting an Immediate FK228
Precursor to FK228
(A) A control reaction without DepH and kept at 80C had 40% reduced
FK228 converted to FK228 due to spontaneous oxidation in prior steps.
(B) Another control reaction without DepH but kept at room temperature had
60% reduced FK228 converted to FK228 due to spontaneous oxidation.
(C) A complete assay had 100% reduced FK228 converted to FK228 in 5 min
or less at room temperature.
(D) Mass spectrum of reduced FK228.
(E) Mass spectrum of FK228.
(F) Michaelis-Menten plot for DepH-catalyzed reactions with varying concen-
trations of reduced FK228 substrate. Error bars refer to standard deviation.r Ltd All rights reserved
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Disulfide Bond Formation in FK228Table 1. Relative Activities of the Wild-Type and Mutants of DepH in Converting Reduced FK228 to FK228
Enzyme Substrates Products Relative Activity (%)
Blank (buffer) Reduced FK228, NADP+ –, – 0
DepH Reduced FK228, NADP+ FK228, NADPH 100
DepH-C156S Reduced FK228, NADP+ FK228, NADPH 7.5
DepH-C159S Reduced FK228, NADP+ FK228, NADPH 3.8
DepH-C156S/C159S Reduced FK228, NADP+ FK228, NADPH 3.6without enzyme but kept at room temperature in a nitrogen gas-
filled chamber had approximately 60% substrate oxidized
(Figure 5B). In a complete assay, 100%of substratewas oxidized
in 5 min or less (Figure 5C). The identity of reduced FK228 and
FK228 (oxidized) was confirmed by subsequent LC-MS analysis
(Figures 5D and 5E). Reduced FK228 with two free thiol groups is
more polar, and was eluted slightly earlier than FK228.
Single point mutants (C156S or C159S) and a double mutant
(C156S/C159S) of the redox motif (CPYC) of DepH were ob-
tained by site-directed mutagenesis, and the mutant proteins
were purified to homogeneity accordingly (Figure S4). The rela-
tive activities of three mutant forms of DepH compared with
that of wild-type DepH were determined (Table 1). It was found
that mutation of either or both cysteine residues in the redox
motif resulted in a drastic reduction of activity, suggesting that
both cysteine residues are critical for enzyme activity.
For steady-state kinetic assays, variable concentrations of
substrate (reduced FK228) were assayed with a fixed amount
of enzyme (DepH) in an appropriate buffer for variable durations
of time at room temperature in a nitrogen environment. Assay
reactions were stopped by mixing with iodoacetamide, which
reacts with free thiol groups to form a stable adduct (Mieyal
et al., 1991). This adduct of reduced FK228 was quantified
by LC-MS analysis. The DepH catalytic parameters toward
reduced FK228 in the presence of NADP+ were determined to
be Vmax = 2.6 ± 0.2 mM min
1, Km = 11.7 ± 0.5 mM, kcat = 1.4 3
102 ± 0.2 min1, and kcat/Km = 12.0 mM
1 $ min1 (Figure 5F).
When NADP+ was replaced by NAD+, the Km was measured to
be 19.4 ± 0.9 mM. Therefore, NADP+ is a preferred electron
acceptor of DepH for the reaction.
DISCUSSION
Disulfide bonds are common in proteogenic biomolecules but
rare in natural products produced nonribosomally by bacteria.
In proteogenic biomolecules such as proteins and peptides, di-
sulfide bonds often serve to maintain structural integrity or to
mediate redox cycling of enzyme activity (Giles et al., 2003; Ka-
dokura et al., 2003). In natural products there are two scenarios
(Figure 1). First, as seen in the quinoxaline family of antibiotics,
disulfide bonds exist either as a transit stage of biosynthesis or
as a part of the final static structure; they might contribute to
the stability of molecules but are not critical for bioactivity.
Second, as seen in FK228 and likely in spiruchostatins as well,
disulfide bonds serve to not only stabilize the molecules in the
form of prodrug, but also mediate the mechanism of bioactivity.
In the last case, once the disulfide bond is opened by cellular
reduction, a freed thiol group selectively chelates the Zn2+ ion
of class I HDACs, thus inhibiting the enzyme activities (NakajimaChemistry & Biology 16et al., 1998). Selective but modest inhibition of HDAC activities
leads to a cascade of epigenetic consequences including chro-
matin remodeling and cancer regression (Bolden et al., 2006).
There have been extensive studies about disulfide bond
formation in proteogenic biomolecules catalyzed by the thiol-
disulfide oxidoreductase family of enzymes (Kadokura et al.,
2003). In contrast, little is known about disulfide bond formation
in natural products, particularly those of bacterial origin. In this
paper, we have characterized DepH as an FAD-dependent
pyridine nucleotide-disulfide oxidoreductase, specifically and
efficiently catalyzing a disulfide bond formation in FK228, an
epigenetically acting anticancer natural product.
Phylogenetic analysis of protein sequences classified DepH,
TdpH, Ecm17, and a few hypothetical proteins into a unique
group of proteins that share a conserved CPY/FC redox motif,
which is different from that (CAT/VC) of the TrxB/TrxR family of
thioredoxin reducatses or that (CXXC) of the Dsb family of
enzymes (Figure 2). Site-directed mutagenesis also confirmed
the essentiality of both cysteine residues in the CPYC motif of
DepH (Table 1). Therefore, the DepH-family of disulfide bond
formation enzymes might represent a new class of oxidoreduc-
tases specifically involved in natural product biosynthesis. We
are in the process of crystallizing DepH, solving its structure,
and further elucidating the mechanism of DepH-catalyzed disul-
fide bond formation in FK228.
Inspired by prior knowledge about reactions catalyzed by
thioredoxin reductase and thioredoxin (Lennon et al., 1999),
here we propose a cascade of reactions that lead to the oxida-
tion of the immediate FK228 precursor to afford FK228 (Figure 6).
In this model, DepH is produced by bacterial cells in an oxidized
form, which grabs electrons from the immediate FK228
precursor (reduced FK228) and passes the electrons through
cofactor FAD on to NADP+/NADPH-mediated oxidative cellular
processes. As a net consequence, the reduced FK228 is
oxidized with the formation of a disulfide bond to become
FK228. Interesting questions to be answered include how
DepH is produced andmaintained in the first place in an oxidized
form in the reducing environment of bacterial cytoplasm, and
whether mature FK228 would be reversibly reduced inside the
bacterial cytoplasm and thus would require constant enzymatic
maintenance.
Deletion of depH led to a drastic decrease of FK228
production by the CvDdepH mutant strain, which confirmed
the critical role of depH in FK228 biosynthesis (Figure 3).
The notably increased accumulation of an immediate FK228
precursor with positive ion signals of [M + 2 + H/Na/K]+ m/z
in the extract of this mutant strain suggests that the immediate
FK228 precursor contains two free thiol groups and that the
oxidative conversion from this precursor to FK228 is indeed, 585–593, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 589
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Disulfide Bond Formation in FK228Figure 6. Proposed Sequence of Oxidation-
Reduction Reactions in the Final Step of
FK228 Biosynthesis
Abbreviations or symbols: FK228=(SH)2, the
reduced form of FK228 (immediate FK228
precursor); FK228=(S-S), the oxidized (natural)
form of FK228; DepH=(SH)2, the reduced form of
DepH; DepH=(S-S), the oxidized form of DepH;
FADox, the oxidized form of FAD; FADred, the
reduced form of FAD.the final step in FK228 biosynthesis. Apparently it takes a dedi-
cated DepH catalyst to efficiently convert the precursor into
FK228 inside the reducing environment of bacterial cells.
Nevertheless, the mutant still produced about 20% as much
FK228 as the wild-type strain. A plausible explanation is that
spontaneous chemical oxidation could slowly convert the
precursor into FK228, despite the reducing microenvironment
of bacterial cells.
However, why is the immediate FK228 precursor in the mutant
strain not accumulated to a level comparable to the FK228 level
in the wild-type strain? We speculate that the precursor with free
thiol groups might be liable to hydrolysis inside or outside of
bacterial cells, or the precursor might be toxic to bacterial cells
by allowing the free thiol groups to interact with some of the
hundreds of Zn2+-containing enzymes (Blencowe and Morby,
2003). If the later speculation were proven true, it could explain
why the C. violaceum no. 968 strain produces FK228 in the
form of a prodrug, because prodrug FK228 with an intact disul-
fide bond is stable, inert, and nontoxic. Prodrug strategy has
become a privileged scheme in modern drug development for
improving physicochemical, biopharmaceutical, or pharmacoki-
netic properties of pharmacologically active agents (Rautio et al.,
2008).
The promising anticancer activities of FK228 and the unique
role of DepH in FK228 biosynthesis entitle the use of the DepH
sequence as bait for genome mining of new biosynthetic gene
clusters that might produce additional FK228-like natural prod-
ucts. In fact, we have identified a strong homolog of DepH that
we named TdpH (GenBank accession number ABC38333),
which is putatively encoded by a gene (BTH_I2359) in the pub-
lished genome of B. thailandensis E264 (Kim et al., 2005).
DepH and TdpH sequences share a 72% identity/85% similarity.
The TdpH-encoding gene is located within a cryptic biosynthetic
gene cluster that shares striking similarity to the FK228 biosyn-
thetic gene cluster, and our laboratory is currently exploring
this finding for the discovery of FK228-like compounds from
B. thailandensis E264.
Furthermore, DepH, TdpH, and Ecm17 are the only known or
proposed enzymes involved in disulfide bond formation in
natural products; therefore, their genes can be exploited in
biosynthetic pathway engineering schemes for the formation of
disulfide bonds in new drug molecules. Similarly, the DepH,
TdpH, and Ecm17 proteins can be exploited in chemoenzymatic
synthesis schemes for in vitro conversion of synthetic precursors
containing two free thiol groups into final productswith adisulfide
bond.
Finally, disulfide bond formation in FK228 biosynthesis ap-
peared to be a rate-limiting step; overexpression of depH has
led to an increased yield of FK228 in the CvDdepH/pBMTL3-590 Chemistry & Biology 16, 585–593, June 26, 2009 ª2009 ElsevierdepH complementant strain as well as in the wild-type control
strain CvWT/pBMTL3-depH (Figure 3). This finding provides
opportunities for improving the yield of FK228 or related natural
products by genetic engineering.
SIGNIFICANCE
The biochemistry of disulfide bond formation in nonriboso-
mally produced natural products, including some important
anticancer agents, is largely unknown. In this work, we
genetically confirmed the involvement of depH in the biosyn-
thesis of FK228, an epigenetically acting anticancer natural
product produced by Chromobacterium violaceum no. 968,
andwebiochemically characterizedDepHasanFAD-depen-
dent pyridine nucleotide-disulfide oxidoreductase, specifi-
cally and efficiently catalyzing a disulfide bond formation in
FK228. Sequence analysis suggested that DepH contains
a signature redox motif CPYC, a conserved FAD-binding
domain, andanNADP+/NADPH-bindingdomain.Wheneither
or both cysteine residues in the redox motif were mutated,
the protein lost most of its catalytic activity. We speculate
that thismotifmight represent a subfamily of disulfideoxido-
reductases specifically involved in secondary metabolism.
We further showed that deletion of depH led to a drastic
decrease of FK228 production, while the relative abundance
of the immediate FK228 precursor increased notably. Inter-
estingly, complementation of the depH-deletion mutant
with depH restored FK228 production to a level 30% higher
than that of the wild-type strain. Additionally, we showed
that purified 6xHis-tagged DepH protein in native form is
a homodimer of 71.0 kDa, with each monomer contains one
molecule of FAD cofactor. Finally we showed that DepH
can efficiently convert the immediate FK228 precursor into
FK228 in the presence of an NADP+ electron acceptor, and
the catalytic parameters are Vmax = 2.6 ± 0.2 mM min
1,
Km = 11.7 ± 0.5 mM, kcat = 1.43 10
2 ± 0.2 min1, and kcat/Km =
12.0 mM1 $ min1. To the best of our knowledge, this work
represents the first biochemical characterization of an
enzyme involved in disulfide bond formation in a nonriboso-
mally produced bacterial natural product.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Media, and Growth Conditions
Bacterial strains and plasmids used in this study are summarized in Table S1.
All chemicals, biochemicals, and media components were purchased from
Fisher Scientific (Pittsburgh, PA), unless otherwise indicated. C. violaceum
no. 968 and E. coli strains were maintained, cultivated, and genetically manip-
ulated as described elsewhere (Cheng et al., 2007), except that only 1% (w/v)Ltd All rights reserved
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Disulfide Bond Formation in FK228Diaion HP-20 (Supelco, Bellefonte, PA) resin was added to fermentation
medium to absorb bacterial byproducts.
DNA Manipulation, PCR, Cloning, and Sequencing
General DNA manipulations were performed according to standard protocols
(Sambrook and Russell, 2000). Bacterial genomic DNA was extracted with an
UltraClean microbial DNA isolation kit fromMO BIO Labs (Carlsbad, CA). DNA
modification enzymes and restriction enzymes were purchased from New
England BioLabs (Ipswich, MA). Oligonucleotide primers were ordered from
Operon (Huntsville, AL). QIAprep plasmid purification kit and QIAEX II gel
extraction kit were from QIAGEN (Valencia, CA). Polymerase chain reaction
(PCR) was performed on a DNA Engine Dyad thermocycler (Bio-Rad,
Hercules, CA). DNA sequencing was performed with an ABI 3730 automated
DNA sequencer (Applied BioSystems, Forster City, CA) at the University of
Wisconsin-Madison Biotechnology Center.
Gene Deletion, FRT Cassette Removal, and Gene Complementation
The general scheme of using a broad host-range Flp-FRT recombination
system for site-specific gene replacement/deletion and marker removal has
been described elsewhere (Choi and Schweizer, 2005; Hoang et al., 1998),
but was modified in this study (Figures S1 and S2).
To construct a depH-gene replacement vector, two DNA fragments (ampli-
cons) were first amplified by PCR from total DNA of the wild-typeC. violaceum
no. 968 strain: a 470 bp 50-end of depH gene fragment (amplicon 1) was ampli-
fied with primer set KpnI-depH-UpF (50-AGGTACCGGGATTCGTCGCTGTTG
C-30) and FRT-F-depH-UpR (50- TCAGAGCGCTTTTGAAGCTAATTCGATCAC
CAGCACGCGGC-30), a 460bp 30-endofdepH gene fragment (amplicon 2)was
amplified with primer set FRT-R-depH-DnF (50- AGGAACTTCAAGATCCCCAA
TTCGACGGGCTGTTCACGATG-30) and BamHI-depH-DnR (50- AGGATCCGC
GCGGCGGCTTTGC-30), and a 1.8 kb FRT cassette containing a Gmr marker
gene and a GFP reporter gene flanked by two FRT recognition sequences
(amplicon 3) was amplified from pPS858 with primer set FRT-F (50-CGAATTAG
CTTCAAAAGCGCTCTGA-30) andFRT-R (50-CGAATTGGGGATCTTGAAGTTC
CT-30). Amplicons 1–3 were assembled into a 2.7 kb amplicon 4 by multiplex
PCR using Long Amp DNA polymerase. Amplicon 4 was digested with KpnI/
BamHI and the insert was subsequently cloned into suicide vector pEX10Tc
to make a depH-gene replacement vector pYC04-18.
To create a depH-gene replacement mutant ofC. violaceum, pYC04-18 was
first transformed intoE. coliS17-1 cells, which subsequently passed the vector
to C. violaceum cells via interspecies conjugation. Mutant strains of C. viola-
ceum with depH partially replaced by the FRT cassette were selected on LB
agar supplemented with 200 mg/ml ampicillin (Ap; C. violaceum is naturally
resistant to Ap up to 500 mg/ml), 50 mg/ml gentamicin, and 5% (w/v) sucrose
at 30C. The genotype of independent mutants was verified by colony PCR
using the primer set depH-F (50-CGACGTCATCGTGATCGGCGGC-30 ) and
depH-R (50- CATTTCCTGAGCGGTCAGGC-30 ) (Figure S2A). One representa-
tive mutant strain was saved and named CvDdepH::FRT.
To create a marker-free mutant by removing the FRT cassette from
CvDdepH::FRT, a broad host-range Flp-expression vector was first construc-
ted. A 5.16 kb SacI/SphI fragment containing the cI857 < Pts-Pl > flp-Psac >
sacB genetic determinants was excised from pFLP2, blunt ended, and cloned
into the EcoRV site of pBMTL-3 to make pBMTL3-FLP2. This vector replicates
in a broad range of bacterial hosts at or above 37C and expresses a site-
specific Flp endonuclease. Vector pBMTL3-FLP2 was introduced into
CvDdepH::FRT by electroporation and marker-free mutants were selected
on LB agar supplemented with 200 mg/ml Ap and 25 mg/ml chloramphenicol
(Cm) at 37C. Vector pBMTL3-FLP2was subsequently cured from themutants
by steaking for two rounds on LB agar supplemented with 200 mg/ml Ap and
5% (w/v) sucrose at 30C. The genotype of independent gene-deletion
mutants was verified by colony PCR using the primer set depH-F and depH-R
(Figure S2B). One final representative marker-free mutant strain was saved
and named CvDdepH.
To complement the CvDdepH mutant and CvWT strain (as control) with
a functional depH gene on a vector, the entire depH ORF (960 bp) was ampli-
fied from genomic DNA with primer set depH-exp-FP (50-GTCTAGACATATGA
AGGCCGCCCGCGCG-30) and depH-exp-RP (50-GCAAGCTTTCACCCGAAC
ACCAACTTGCG-30). This product was digested with NdeI/HindIII and the
insert was cloned into pET29a to make pET29a-depH intermediate construct.Chemistry & Biology 16The depH ORF along with an upstream ribosomal binding site from the vector
was excised by XbaI/HindIII digestion from pET29a-depH and cloned into
pBMTL-3 to make the final depH complementation vector pBMTL3-depH.
The gene fidelity was verified by resequencing and the vector was introduced
by conjugation into CvDdepH mutant to create a complementation strain
CvDdepH/pBMTL3-depH and into CvWT to create a control strain CvWT/
pBMTL3-depH.
Bacterial Fermentation, Extraction, Identification,
and Quantification of FK228, and Preparation of Reduced FK228
Fermentation of the CvWT strain, CvDdepHmutant strain, CvDdepH/pBMTL3-
depH complementant strain, and CvWT/pBMTL3-depH control strain of
C. violaceum in 50 ml nutrient broth supplemented with 200 mg/ml Ap, 1%
(w/v) of Diaion HP-20 resins, and with 0.5% (v/v) lactose (lactose induces the
expression of depH on the pBMTL-3 vector) for 4 days at 30C, was performed
similarly as described elsewhere (Cheng et al., 2007). After fermentation resins
and cell debris of each strain were collected by centrifugation and lypholized to
dryness. Tenml of ethyl acetatewas used to extract the driedmass and 20 ml of
such organic extract was analyzed with an Agilent 1100 series LC/MSD Trap
mass spectrometer (Agilent, Santa Clara, CA) for the detection and quantifica-
tionof FK228production by relating thepeak area of ion signals to that of FK228
standard, as described elsewhere (Cheng et al., 2007; Hwang et al., 2004).
A larger quantity of FK228waspurified from15 L fermentation culture ofwild-
type C. violaceum according to a previously published procedure (Ueda et al.,
1994), and saved as amorphous powder at20C until use. To prepare for the
immediate FK228 precursor (reduced FK228 with two free thiols), a proper
amount of FK228 was redissolved in acetonitrile/water (20% v/v) and mixed
overnight at room temperature with 50 mM DTT. Reduced FK228 (almost
100% reduction) was purified from reaction mixture by preparative HPLC on
a ProStar HPLC system (Varian, Walnut Creek, CA) with a 10 mm particle
size, 21.2 3 250 mm Prep-C18 column (Agilent). A gradient from 100% buffer
A (20% acetonitrile) to 100% buffer B (100% acetonitrile) was achieved in
30 min. The fraction containing the reduced FK228 was lypholized and stored
airtight at20C until use. Reduced FK228 was readily redissolved in acetoni-
trile tomakesuitable concentrationsof substrate solution for enzymatic assays.
DepH Overexpression and Purification, and Site-Directed
Mutagenesis
The previously amplified depH ORF (960 bp) was cloned into the NdeI/HindIII
sites of pET28a to make pCW01-1212 in E. coli DH5a cells. The DNA fidelity
was verified by sequencing and the vector was introduced into E. coli
BL21(DE3) cells for protein overexpression and purification.
E. coli BL21(DE3)/pCW01-1212 was cultured in 4 L LB medium supple-
mented with 50 mg/ml kanamycin at 37C to reach an OD600 of 0.6. Then
IPTGwas added to a final concentration of 0.05mM to induce gene expression
and the cells were further cultured at 28C for 12 hr. Cells were harvested
by centrifugation and resuspended in 50 ml lysis buffer (50 mM phosphate
[pH 7.0], 300 mM NaCl, 0.1% [v/v] Tween-20, and two complete EDTA free
protease inhibitor cocktail tablets [Roche, Indianapolis, IN]). Cells were broken
by passing twice through a French Press (Sim-Aminco) and cell lysate was
clarified by centrifugation at 48,400 g for 30 min at 4C. The resulting superna-
tant was loaded on a Ni-NTA agarose column (QIAGEN) that was equilibrated
with a wash buffer (50mMphosphate [pH 7.0], 300mMNaCl, and 20mM imid-
azole) and the column was washed extensively with the same wash buffer.
DepH was eluted with an elution buffer (50 mM phosphate [pH 7.0], 300 mM
NaCl, and 250 mM imidazole). The purified protein was dialyzed using a 6–
8 kDa Spectra/Pro membrane tubing (Spectrum; Gardena, GA) at 4C against
a storage buffer (20 mM Tris-HCl [pH 7.0], and 100 mM NaCl) overnight.
Because DepH is expected to exist naturally in an oxidized form with an intact
disulfide bond, no reducing agent (e.g., DTT or 2-mercaptoethanol) was added
to the purification steps. The purity of DepH was assessed by SDS-PAGE and
the protein concentration was determined by Bradford assay (Bradford, 1976),
using bovine serum albumin as a standard. Finally aliquots of DepH were flash
frozen and stored at 80C until use.
Site-directed mutagenesis to create single mutants (C156S or C159S) and
a double mutant (C156S/C159S) of DepH were accomplished using the Quik-
Change Lightning Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA)
and the following primer pairs (where underlined letters indicate base, 585–593, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 591
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C156S-R (50-CGTGGCAGTAAGGGGAGTGGAACACGCTTTCC-30 ), C159S-F




depH genes based on pCW01-1212 were verified by sequencing, and mutant
proteins were purified with the same procedure as for the wild-type DepH.
Determination of Physical and Biochemical Properties of DepH
The oligomeric status of DepH was determined by size exclusion chromatog-
raphy at 4C using the A¨KTA Prime FPLC equipped with a HiPrep Sephacryl
26/60 S300 high-resolution column (GE Life Sciences, Piscataway, NJ).
Running buffer used was 20 mM Tris-HCl (pH 7.0) and 100 mM NaCl, and the
flow rate was 0.5 ml/min. Protein elution was monitored at UV280. To establish
a reference curve, gel-filtration molecular weight markers (Sigma-Aldrich)
including blue dextran (2000 kDa), amylase from sweet potato (200 kDa),
alcohol dehydrogenase from yeast (150 kDa), bovine serum albumin (66 kDa),
carbonic anhydrase from bovine (29 kDa), and cytochrome c from horse heart
(12.4 kDa) were used. DepH was analyzed separately or in combination with
some markers under the same conditions.
Ultraviolet and visible (UV/Vis) spectra of DepH (36 mM in 20 mM Tris-HCl
[pH 7.0] and 100mMNaCl buffer) and FAD standard (25 mM in the same buffer)
from 200 to 800 nmwere obtained sequentially with Cary 100 Bio spectropho-
tometer (Varian, Walnut Creek, CA) at room temperature.
The presence of FAD cofactor in DepH was determined by HPLC and
LC-MS analysis. Separation of sample was performed on a ProStar HPLC
system from Varian, equipped with the Eclipse XBD C18 column (5 mmparticle
size, 4.63 250mm) fromAgilent. Flow rate wasmaintained at 1ml/min and the
column was equilibrated with a buffer mixture of 85% solvent A (5 mM ammo-
nium acetate [pH 6.5]/15% solvent B [100% methanol]). DepH (36 mM) was
denatured by boiling at 100C for 5 min to free the cofactor. Denatured
protein was removed by centrifugation and 20 ml supernatant was analyzed
by HPLC. A linear gradient from the equilibration stage to a final buffer compo-
sition of 25% solvent A/75% solvent B was achieved in 20 min. The ultraviolet
irradiation absorbance of cofactor wasmonitored at 264 nm. An HPLC fraction
containing the cofactor was dried in vacuo, resuspended in 50 ml acetonitrile,
and examined by LC-MS analysis. FAD standard (25 mM) was used as a
reference.
The stoichiometry of DepH-FAD was determined in duplicate as follows.
An aliquot of DepH (36 mM) was saturated with an excess amount of FAD
(1 mM) at 4C overnight and was then dialyzed against the storage buffer
(20 mM Tris-HCl [pH 7.0], and 100 mM NaCl) to remove unbound FAD.
DepH concentration was redetermined using Bradford assay. DepH was
subsequently denatured by boiling for 5 min to release bound FAD. FAD
concentration was determined from the absorption at 450 nm, measured on
a Cary 100 Bio spectrophotometer (Varian) at room temperature, using amolar
extinction coefficient of A450 = 11.0 mM
1 $ cm1. Buffer was used as a blank
for background subtraction.
Determination of Enzyme Activity and Enzyme Kinetics
Enzyme Activity of the Wild-Type and Mutated Forms of DepH
First, the reaction buffer (20 mM Tris-HCl [pH 7.0], 100 mM NaCl, with 200 mM
NADP+) used in assays was purged extensively with bubbling of nitrogen gas.
For a complete assay, 5 ml reduced FK228 (100 mM) and 1 ml enzyme solution
(36 mM) were added into 95 ml reaction buffer and the reaction was allowed to
proceed for 5 min at room temperature in a nitrogen-gas-filled chamber. Each
reaction was quenched with 400 ml ice-cold acetone for 5 min on ice. Acetone
was then removed by a flow of nitrogen gas and the remaining solution was
analyzed with LC-MS. Enzyme was omitted from control reactions, which
were kept either in a 80C freezer or at room temperature, and received
the same treatment as the complete reaction until LC-MS analysis. The total
time needed from the start of reaction to LC-MS analysis was about 20 min.
All reactions were assayed in duplicate.
Enzyme Kinetics of DepH
Due to a high rate of reaction and unavoidable spontaneous chemical oxida-
tion, the assay conditions were optimized by numerous tests (data not shown).
The reactions were performed in 30 ml buffer (20mMTris-HCl [pH 7.0], 100mM592 Chemistry & Biology 16, 585–593, June 26, 2009 ª2009 ElsevieNaCl, 200 mM NADP+ or NAD+) at room temperature in a nitrogen-gas-filled
chamber. Variable concentration of substrate (reduced FK228, from 2 to
80 mM final concentration) and fixed amount of enzyme DepH (0.02 mg;
18 nM final concentration) was added into each reaction. Five microliters of
500 mM iodoacetamide was used to stop reactions and to block free thiol
groups at different time points (0, 0.5, 1, 2, and 4 min). Afterwards, 20 ml of
each reaction mixture was analyzed with LC-MS. All reactions were assayed
in duplicate. Values from the 0 min time point were used for background
subtraction.
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